Named Bioactive Compounds · Compound
Galangin
Moderate Evidencecompound
Hermetica Superfood Encyclopedia
Galangin is a flavonoid compound found primarily in propolis and Alpinia galanga that exhibits anti-tumor and antidiabetic properties. It works by inhibiting PD-L1 expression to enhance immune response and blocking DPP-4 enzyme to improve glucose metabolism.
Galangin is a natural flavonoid (specifically a flavonol) primarily extracted from the rhizomes of Alpinia officinarum (galangal) and propolis, as well as other plants like Helichrysum aureonitens. It is typically obtained through solvent extraction methods from these plant materials.
Current evidence for galangin is limited to preclinical studies, with no human clinical trials, RCTs, or meta-analyses identified. Key research includes in vitro and xenograft studies on PD-L1 inhibition (PMID: 37267692), DPP-4 inhibition in rat cells (PMID: 30862104), and diabetic nephropathy models in rats using 15 mg/kg doses (PMID: 34099583).
No clinically studied human dosages are available. Animal studies have used 15 mg/kg/day orally for 8 weeks in diabetic rats. Human dosing, standardization, and optimal forms remain unestablished. Consult a healthcare provider before starting any new supplement.
Galangin (3,5,7-trihydroxyflavone) is a naturally occurring flavonol (molecular formula: C₁₅H₁₀O₅, molecular weight: 270.24 g/mol) found primarily in Alpinia officinarum (lesser galangal) rhizome at concentrations of approximately 0.1–1.5% dry weight, as well as in propolis (particularly from Apis mellifera, ~10–15% of total flavonoid content in some varieties) and honey in trace amounts. It is not a macronutrient source and provides negligible calories, protein, fat, fiber, or carbohydrates at pharmacologically relevant doses. Key bioactive characteristics include: • Flavonol backbone with hydroxyl groups at C-3, C-5, and C-7 positions, lacking B-ring hydroxylation, which distinguishes it from kaempferol and quercetin and contributes to its relatively higher lipophilicity among flavonols (log P ~2.1). • Contains no vitamins or minerals itself but co-occurs in galangal rhizome alongside other bioactive flavonoids such as kaempferide (~0.05–0.5% dry weight) and alpinin, as well as volatile oils (1,8-cineole, methyl cinnamate). • Bioavailability is limited due to poor aqueous solubility (~11 µg/mL in water at 25°C), rapid Phase II metabolism (extensive glucuronidation and sulfation in intestinal and hepatic tissues), and relatively short plasma half-life. Oral bioavailability in rodent models is estimated at <10%. • Undergoes significant first-pass metabolism; primary metabolites include galangin-7-O-glucuronide and galangin-7-O-sulfate, which may retain partial biological activity. • Absorption may be enhanced by co-administration with piperine or lipid-based delivery systems (nanoencapsulation has shown 3–5× improved bioavailability in preclinical studies). • Antioxidant capacity: ORAC values are moderate among flavonols; acts primarily through direct free radical scavenging (particularly superoxide and hydroxyl radicals), chelation of transition metal ions (Fe²⁺, Cu²⁺), and upregulation of endogenous antioxidant enzymes (SOD, catalase, GPx) via Nrf2/ARE pathway activation. • Exhibits interactions with multiple molecular targets at micromolar concentrations in vitro, including COX-2, CYP1A1, aromatase (CYP19), xanthine oxidase (IC₅₀ ~2–10 µM), and various kinases relevant to its reported anti-inflammatory and anticancer properties.
Galangin inhibits programmed death-ligand 1 (PD-L1) expression on tumor cells, allowing T-cells to maintain their cytotoxic activity against cancer cells. It also blocks dipeptidyl peptidase-4 (DPP-4) enzyme, which normally degrades incretin hormones, leading to improved insulin sensitivity and glucose uptake in cells.
Current evidence for galangin comes primarily from in vitro cell studies and animal models rather than human clinical trials. Cell culture studies demonstrate PD-L1 inhibition and enhanced T-cell activity against tumor cells. Rat studies show DPP-4 inhibition leading to improved glucose metabolism, but effective dosages and safety profiles in humans remain unclear. Large-scale human trials are needed to confirm these preliminary benefits.
Safety data for galangin supplementation in humans is limited due to lack of clinical trials. As a flavonoid, it may interact with cytochrome P450 enzymes, potentially affecting drug metabolism. Individuals taking diabetes medications should exercise caution due to potential additive blood sugar lowering effects. Pregnant and breastfeeding women should avoid galangin supplements due to insufficient safety data.
